TY  - GEN
AU  - Cassinello, J
AU  - Arranz, J Á
AU  - Piulats, J M
AU  - Sánchez, A
AU  - Pérez-Valderrama, B
AU  - Mellado, B
AU  - Climent, M Á
AU  - Olmos, D
AU  - Carles, J
AU  - Lázaro, M
PY  - 2017
DO  - 10.1007/s12094-017-1783-2
UR  - http://hdl.handle.net/20.500.12105/17346
AB  - Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been...
LA  - eng
KW  - Abiraterone
KW  - Androgen deprivation treatment
KW  - Cabazitaxel
KW  - Castration-resistant prostate cancer
KW  - Docetaxel
KW  - Enzalutamide
KW  - Hormone-sensitive advanced prostate cancer
KW  - Radium 223
KW  - Antineoplastic Agents
KW  - Humans
KW  - Male
KW  - Prostatic Neoplasms
TI  - SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
TY  - research article
ER  -